Fierce Pharma
SEPTEMBER 9, 2022
Regeneron exec says it’s ‘just the beginning’ for Dupixent in type 2 inflammation, as the Sanofi-partnered blockbuster clinches another win ahead of FDA verdict in prurigo nodularis. fkansteiner. Fri, 09/09/2022 - 09:31.
World of DTC Marketing
SEPTEMBER 7, 2022
Wall Street wants growth, as do investors, but that may be impossible for pharmaceutical companies. In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. Biogen’s failure should be a warning to other pharma companies. They relied so much on a new drug that they tried to market a product with bad science behind it.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
SEPTEMBER 3, 2022
The breast cancer solution will help determine which patients would benefit from targeted therapies and which patients could avoid chemotherapy. Meanwhile, the colorectal solution will be able to match patients with the most effective treatment sooner.
pharmaphorum
SEPTEMBER 5, 2022
Sam Crowther, founder and CEO of cybersecurity company Kasada, tells us about a recent discovery his company made that revealed tens of thousands of accounts with prescription drug attachments in major online pharmacies had been compromised. While performing analysis for a client of online accounts for sale, Kasada uncovered a new and illegal way bots are being used – to steal pharmacy customers’ accounts and resell prescriptions on a secondary market for in-demand substances, such as Oxyc
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
.png)
Fierce Pharma
SEPTEMBER 6, 2022
GSK's daprodustat will have to face FDA expert panel first as oral CKD anemia prospect targets nod that stumped AstraZeneca, Otuska rivals. fkansteiner. Tue, 09/06/2022 - 16:05.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
SEPTEMBER 8, 2022
Medical IoT is forecast to grow from $41 billion in 2020 to $188 billion by 2028. The growth is for a good reason: Connected medical devices, combined with the right software, can improve conditions and delivery, optimize care and devices, and save lives.
pharmaphorum
SEPTEMBER 7, 2022
Brainomix has reeled in another pharma partner for its artificial intelligence-powered biomarker software, used to track the performance of therapeutic interventions in clinical trials. South Korea’s Bridge Biotherapeutics has signed up to use the UK medtech firm’s e-ILD software package in a phase 2 trial of BBT-877, its experimental therapy for serious lung disease idiopathic pulmonary fibrosis (IPF).
Fierce Pharma
SEPTEMBER 8, 2022
ESMO: Gilead's Trodelvy makes surprise comeback with above-par breast cancer survival showing. aliu. Wed, 09/07/2022 - 15:14.
Medgadget
SEPTEMBER 7, 2022
Researchers at Rice University have developed a pneumatic assistive device for people with disabilities. The technology includes an air pump that is mounted in the wearer’s shoe, providing pneumatic power with each step. This power is stored in a wearable belt that includes an “arm” that can reach out and grip items when activated. The device may be very practical for people with arm weakness who struggle to lift objects.
MedCity News
SEPTEMBER 7, 2022
One organization piloted a smart speaker system in its spinal injuries unit. Over the course of four weeks, patients interacted with the automated assistant more than 5,000 times. Sixty-three percent of nurses on the unit found the pilot improved their ability to deliver and prioritize patient care.
European Pharmaceutical Review
SEPTEMBER 7, 2022
The second most commonly used pharmaceutical dosage form, capsules, are anticipated to be a $5.2 billion market by 2030, growing from a 2020 value of around $2.4 billion. 1 Here experts Torkel Gren of Recipharm and Dr Jnanadeva Bhat of ACG-Worldwide share key developments in capsules by answering four key questions. What are the major trends in capsule development?
Fierce Pharma
SEPTEMBER 6, 2022
Bayer pays $40M to settle with whistleblower who said company violated False Claims Act. kdunleavy. Tue, 09/06/2022 - 09:08.
Medgadget
SEPTEMBER 7, 2022
A team at the University of Michigan has developed a coating for frequently touched surfaces that can rapidly kill a wide array of pathogens, including MRSA and SARS-CoV-2. The technology incorporates polyurethane that contains crosslinked compounds from essential oils with wide-spectrum anti-microbial action. The researchers fine-tuned the crosslinking process so that the oils were available to kill microbes but not sufficiently free to evaporate rapidly.
MedCity News
SEPTEMBER 7, 2022
The drive to “fix healthcare” is ingrained in our society. Politicians speak about it regularly, consumers struggle to understand it, and yet the “how” of fixing it is delivered with ambiguity and jargon. With increased urgency to improve healthcare, everyone is now laser focused on this topic. But, over time, the term “healthcare” itself has lost the part about care.
PharmaVoice
SEPTEMBER 6, 2022
From standout executives to R&D pioneers — this year’s class of honorees is defining the next era of leadership.
Fierce Pharma
SEPTEMBER 9, 2022
ESMO: AstraZeneca, Merck tout Lynparza's 'clinically meaningful' ovarian cancer survival edge but lose one in prostate cancer. aliu. Fri, 09/09/2022 - 10:58.
Pharmaceutical Technology
SEPTEMBER 5, 2022
Following AstraZeneca’s success in vaccine development during the Covid-19 pandemic , the pharmaceutical giant is now looking to expand its scope through acquisitions across a range of indications, says CEO Pascal Soriot. “We want to be a sustainably growing company. Until 2025, we have strong growth ahead of us, but we also believe we can continue to grow very strongly post-2025 and it’s all about innovation in the pipeline.”.
MedCity News
SEPTEMBER 3, 2022
Kochava allegedly sold geolocation data from hundreds of millions of cell phones that showed people’s visits to reproductive health clinics, places of worship, homeless and domestic violence shelters and addiction recovery facilities. .
pharmaphorum
SEPTEMBER 9, 2022
Digital health specialist Kry has teamed up with pharma group Novo Nordisk on the development of resources that can help people with obesity manage their condition and adhere to treatment. The partners anticipate that the digital obesity programme will launch later this autumn in Sweden, ahead of a broader rollout in other European markets before the end of the year.
Fierce Pharma
SEPTEMBER 8, 2022
'The Top Line': Sarepta's DMD trial set to regain momentum, Illumina's quest for Grail sees opposing results. tcarey. Thu, 09/08/2022 - 12:59.
Pharmaceutical Technology
SEPTEMBER 8, 2022
Roche has signed a definitive merger agreement for the acquisition of US-based biopharmaceutical company Good Therapeutics for an upfront payment of $250m in cash. Good Therapeutics focuses on the development of PD-1-regulated IL-2 drugs that are based on innovative conditionally active drug technology. With the takeover, Roche will attain rights to a conditionally active, PD-1-regulated IL-2 programme of Good Therapeutics.
MedCity News
SEPTEMBER 8, 2022
Through the collaboration, UnitedHealth Group’s Optum will use its analytics and support tools to help Walmart Health clinicians deliver value-based care to Medicare Advantage beneficiaries. The partnership is starting at 15 locations in Florida and Georgia with the potential to grow in the future.
pharmaphorum
SEPTEMBER 6, 2022
NICE has said it is unable to recommend NHS use of AstraZeneca’s Lynparza for some patients with prostate cancer, after failing to reach an agreement on price with the drugmaker. The health technology assessment (HTA) authority said that the PARP inhibitor “is not cost-effective at its current price” as a treatment for BRCA-positive prostate cancer that has spread to other parts of the body and relapsed after prior hormonal therapy.
Fierce Pharma
SEPTEMBER 9, 2022
Arcutis' roflumilast clinches win in seborrheic dermatitis trial, proving it's no one trick pony in itch. fkansteiner. Fri, 09/09/2022 - 11:10.
Medgadget
SEPTEMBER 7, 2022
Researchers at MIT have developed an AI system that can diagnose Parkinson’s disease and track its progression, simply by monitoring someone’s breathing patterns as they sleep. The device looks like an internet router and can be mounted on the wall in a bedroom. It emits radio waves and then a neural network analyzes the reflected waves to assess breathing patterns.
MedCity News
SEPTEMBER 8, 2022
uMETHOD, which provides precision medicine software to treat cognitive decline, tapped at-home diagnostics provider Getlabs to supply mobile phlebotomies for its patients in Arizona. Blood tests are an essential part of the personalized care plans that uMETHOD provides, and the partnership seeks to make these tests accessible to patients with cognitive decline.
pharmaphorum
SEPTEMBER 8, 2022
Asking patients with chronic conditions to regularly inject themselves can be challenging, causing needle anxiety and worry that they may not carry out the procedure correctly, which can reduce compliance. Now, a partnership between Ypsomed and Sidekick Heath aims to tackle that problem. Ypsomed is a top developer of injection and infusion systems, so knows a lot about the difficulties that patients can face when getting to grips with these medical devices, particularly when they are just starti
Fierce Pharma
SEPTEMBER 8, 2022
With long-awaited FDA nod, Revance set to take on AbbVie's Botox with its longer-lasting Daxxify. kdunleavy. Thu, 09/08/2022 - 08:14.
Pharmaceutical Technology
SEPTEMBER 5, 2022
The National Medical Products Administration of China (NMPA) has approved CanSino Biologics ’ (CanSinoBIO) recombinant Covid-19 vaccine (Adenovirus Type 5 Vector) for inhalation, Convidecia Air, as a booster. This vaccine leverages the same adenovirus vector technological platform as Convidecia, the intramuscular version. Providing a non-invasive option, Convidecia Air utilises a nebuliser to convert liquid into an aerosol for inhaling through the mouth, the company noted.
MedCity News
SEPTEMBER 3, 2022
Especially today, when more mothers’ health may be at risk, we can reduce potential harm and save thousands of lives through more evidence-based education, continuous training, and awareness that will help our obstetric care teams make informed and accurate medical decisions with effective interventions that mitigate complications early and often.
pharmaphorum
SEPTEMBER 8, 2022
Ben Hargreaves examines what advantages radiopharmaceuticals offer in the treatment of cancer and why there has been interest from big pharma in developing these types of therapies. The article also outlines some of the challenges remaining to be tackled. Radiotherapy dates back more than a hundred years, yet it still remains a core part of cancer treatment today.
Fierce Pharma
SEPTEMBER 8, 2022
Former J&J executive settles with company in workplace discrimination lawsuit. zbecker. Thu, 09/08/2022 - 11:32.
Pharmaceutical Technology
SEPTEMBER 5, 2022
Bayer has agreed to make a payment of $40m for settling claims over the alleged violations of the False Claims Act linked to three drugs, Trasylol, Avelox and Baycol, the US Department of Justice said in a press statement. The settlement comes after a former Bayer employee, Laurie Simpson, filed two 'whistleblower' lawsuits against the company. These litigations were filed under the qui tam or whistleblower provisions of the False Claims Act, which facilitate private citizens to file lawsuits ag
Expert insights. Personalized for you.
246 
Let's personalize your content